Abstract
Purpose
This study aims to describe innovation profile in the field of personalized medicine. While the major market players have recognized the importance of personalizing health care as the next milestone towards improved clinical outcomes, a common framework has yet to emerge. In the absence of such governance framework, the practices of research and development can shape the progress of the field. The cognitive structure of the research and development in the personalized medicine is mapped by characterizing the attributes of underlying technological space.
Methods
By exploring the technological trajectory and emerging patterns of personalized medicine discerned in patenting activity and citation relations, a detailed picture of innovation in the field is obtained. Moreover, a topic modeling technique was applied to understand the emergence and institutionalization of new technological fields.
Results
The results show that the patent landscape is dominated by therapeutic patents used in the oncology and therapeutic areas of neurodegenerative and infectious diseases. Increase in funding for the proper cycling between research, clinical care, and cost management program would accelerate the adoption of precision medicine and promote the convergence of IT-driven data science and the traditional natural sciences.
Conclusions
This work offers a complementary perspective to the field of personalized medicine, focusing on the exploitation of patent information. We expect that systematic understanding of the technology landscape and evolving R&D process in the personalized medicine may help to provide insights for making future technology planning more rationally.
Similar content being viewed by others
References
Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19(12):491–6.
Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet. 2005;14(2):R207–14.
Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–87.
Valdes AM, Glass D, Spector TD. Omics technologies and the study of human ageing. Nat Rev Genet. 2013;14(9):601–7.
Willard HF, Angrist M, Ginsburg GS. Genomic medicine: genetic variation and its impact on the future of health care. Philos Trans R Soc B. 2005;360(1460):1543–50.
Hamburg MA, Collins FS. The path to personalized medicine. New Engl J Med. 2010;363(4):301–4.
Seo D, Ginsburg GS. Genomic medicine: bringing biomarkers to clinical medicine. Curr Opin Chem Biol. 2005;9(4):381–6.
Grech G. Grossman, introduction. In: Grech G, Grossman I, editors. Preventive and predictive genetics: towards personalised medicine. Cham: Springer International Publishing; 2015. p. 1–6.
Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526(7573):336–42.
Mittra J, Tait J. Analysing stratified medicine business models and value systems: innovation-regulation interactions. New Biotechnol. 2012;29(6):709–19.
Anonymous. Precision Medicine Initiative: data security policy principles and framework. In: The White House. 2016. https://www.whitehouse.gov/sites/whitehouse.gov/files/documents/PMI_Security_Principles_Framework_v2.pdf Accessed 25 May 2016.
Office of the Press Secretary. FACT SHEET: President Obama’s Precision Medicine Initiative. In: The White House. https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative Accessed 25 May 2016.
Snyderman R, Drake CD. Personalized healthcare: unlocking the potential of genomic and precision medicine. J. Precision Med. 2015: 38–41.
Bahcall O. Precision Medicine. Nature. 2015;526(7573):335.
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50.
Deverka PA, Doksum T, Carlson RJ. Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin Pharmacol Ther. 2007;82(4):427–34.
Chataway J, Fry C, Marjanovic S, Yaqub O. Public-private collaborations and partnerships in stratified medicine: making sense of new interactions. New Biotechnol. 2012;29(6):732–40.
Keeling P, Roth M, Zietlow T. The economics of personalized medicine: commercialization as a driver of return on investment. New Biotechnol. 2012;29(6):720–31.
Tutton R, Jamie K. Personalized medicine in context: a social science perspective. Drug Discov Today Ther Strateg. 2013;10(4):e183–7.
Bubela T, Gold ER, Graff GD, et al. Patent landscaping for life sciences innovation: toward consistent and transparent practices. Nat Biotechnol. 2013;31(3):202–6.
Schulman KA, Vidal AV, Ackerly DC. Personalized medicine and disruptive innovation: implications for technology assessment. Genet Med. 2009;11(8):577–81.
Narin F. Patents as indicators for the evaluation of industrial research output. Scientometrics. 1995;34(3):489–96.
Blei DM, Lafferty JD. Topic models. In: Srivastava AN, Sahami M, editors. Text mining: classification, clustering, and applications. Boca Raton: CRC press; 2009. p. 71–94.
Blei DM. Probabilistic topic models. Commun ACM. 2012;55(4):77–84.
Kaplan S, Vakili K. The double-edged sword of recombination in breakthrough innovation. Strategic Manage J. 2015;36(10):1435–57.
Klein RD. Gene patents and genetic testing in the United States. Nat Biotechnol. 2007;25(9):989–90.
Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003;300(5617):286–90.
Graff GD, Phillips D, Lei Z, et al. Not quite a myriad of gene patents. Nat Biotechnol. 2013;31(5):404–10.
Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM. Gene patenting—the Supreme Court finally speaks. New Engl J Med. 2013;369(9):869–75.
Offit K, Bradbury A, Storm C, et al. Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology. J Clin Oncol. 2013;31(21):2743–8.
Ledford H. Myriad ruling causes confusion. Nature. 2013;498(7454):281–2.
Sassoon I, Blanc V. Antibody–drug conjugate (ADC) clinical pipeline: a review. In: Ducry L, editor. Antibody-drug conjugates. New York: Humana press; 2013. p. 1–27.
Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–32.
Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov. 2009;8(4):279–86.
Acknowledgements
This work was supported by Medical Research Center programs to J.W.H through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2012R1A5A2A28671860). The authors would like to thank the editor and the anonymous reviewers of Journal of Pharmaceutical Innovation for their insightful comments and feedback on this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Song, C.H., Han, JW., Jeong, B. et al. Mapping the Patent Landscape in the Field of Personalized Medicine. J Pharm Innov 12, 238–248 (2017). https://doi.org/10.1007/s12247-017-9283-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12247-017-9283-z